Abstract
Coronavirus disease 2019 (COVID-19) is a form of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has been declared a pandemic by the World Health Organization (WHO). Ocular manifestations related to COVID-19 are uncommon with conjunctivitis being reported in a few cases. We report a unique case of vasculitic retinal vein occlusion (RVO) secondary to COVID-19 in a 52-year-old patient who presented with the diminution of vision in the left eye 10 days after he tested positive for SARS-CoV-2. All investigations for vasculitis were negative. This case supports the mechanism of thrombo-inflammatory state secondary to the "cytokine-storm" as the pathogenesis for systemic manifestations of COVID-19.
Keywords:
COVID-19; SARS-CoV-2; retinal vein occlusion; vasculitis.
MeSH terms
-
Administration, Oral
-
Angiogenesis Inhibitors / therapeutic use
-
Betacoronavirus / pathogenicity*
-
COVID-19
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / virology*
-
Drug Therapy, Combination
-
Eye Infections, Viral / diagnosis
-
Eye Infections, Viral / drug therapy
-
Eye Infections, Viral / virology*
-
Fluorescein Angiography
-
Glucocorticoids / therapeutic use
-
Humans
-
Intravitreal Injections
-
Male
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Pandemics
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy
-
Pneumonia, Viral / virology*
-
Ranibizumab / therapeutic use
-
Retinal Vasculitis / diagnosis
-
Retinal Vasculitis / drug therapy
-
Retinal Vasculitis / virology*
-
Retinal Vein Occlusion / diagnosis
-
Retinal Vein Occlusion / drug therapy
-
Retinal Vein Occlusion / virology*
-
SARS-CoV-2
-
Tomography, Optical Coherence
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Glucocorticoids
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Methylprednisolone
-
Ranibizumab